Cheng Hsin General Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2021

  1. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

    Multiple Sclerosis and Related Disorders, Vol. 47

  2. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

    Annals of Neurology, Vol. 89, Núm. 6, pp. 1088-1098